Marvel Biosciences Corp. awarded 50,001 deferred share units (DSUs) to its three independent directors as payment for their fees, replacing cash payments. These DSUs will vest on May 19, 2027, and will be settled when the directors leave the company. The value of the DSUs is based on the company's share price of $0.15 as of May 19, 2026. Marvel Biosciences is developing a new drug candidate, MB-204, targeting neurological diseases, with potential applications beyond Parkinson's, including autism and Alzheimer's disease.
Nvidia posted an 85% year-over-year revenue increase and raised its full-year 2027 guidance, underscoring its leadership in AI technology development. Despite strong earnings, the stock's price movement suggests investors worry that much of the poten...
Wells Fargo raised its price target for Marvell Technology to $195 from $135, citing AWS Trainium deployment and custom silicon momentum, while Oppenheimer increased its target to $200 from $170 ahead of quarterly results. Both firms highlight Marvel...
Marvell Technology's stock has doubled year-to-date, driven by Nvidia's $2 billion investment and strong future revenue guidance. The company raised its FY2027 revenue forecast to $11 billion, indicating over 30% growth fueled by custom silicon and A...
Marvell Technology's stock surged nearly 97% year-to-date in 2026, driven by strong demand for its AI data center chips and record fiscal 2026 revenue of $8.195 billion, up 42% year-over-year. Several U.S. Congress members, including those on financi...
Amazon increased its stake in Marvell Technology by purchasing 170,924 shares in Q1, raising its total to 396,352 shares valued at $39.26 million. This move highlights Amazon's commitment to its AI infrastructure, as Marvell co-designs chips like Tra...
